CMS-1 (Cellular Metabolic Stabilizer) Formulation History
Document ID: NERC-CHEM-2225-CMS1
Classification: Restricted Medical Registry
Primary Author: Dr. Alex Cruiz (Neurology & Radiation Medicine, New Eden)
This dossier tracks the quantitative evolution of the CMS-1 chemical standard—moving from an emergency maternal intervention to an aggressive, life-sustaining pediatric and adult neuro-fuel.
Overview of Longitudinal Evolutionary Needs
The baseline objective of CMS-1 shifted over a thirty-year timeline. What began as an attempt to calcify and reinforce failing maternal vascular tissue became a highly bioretentive fluid designed to feed a massive 2.5x Basal Metabolic Rate (BMR) without destroying skeletal development.
- Jenni (Maternal): Focus on vascular elasticity, soft tissue defense, and halting bone-density stripping[cite: 1, 2].
- Neonatal Celectra: Focus on basic caloric survival, high lipid ratios for myelin generation, and stabilizing core temperature (38.5°C)[cite: 1, 2].
- Mid-Childhood Celectra: Focus on structural skeletal growth while simultaneously feeding the iron-magnesium skull-lacing matrix[cite: 2].
- Young Adulthood Celectra: Focus on raw glucose delivery and high-efficiency ion balancing for high-bandwidth EM communion[cite: 1, 2].
Comparative Formulation Matrix (Per 1,000 mL Base Suspension)
| Core Component Category | Specific Ingredient | Jenni (Maternal Therapeutic) | Celectra (Neonatal Stabilizer) | Celectra (Mid-Childhood) | Celectra (Young Adult / Active) |
|---|---|---|---|---|---|
| Primary Lipid & Brain Fuel | MCT Emulsions[cite: 1] | 50 mL (Low-density) | 450 mL (Critical Myelin-Base) | 250 mL | 350 mL[cite: 1] |
| Waveguide Minerals[cite: 2] | Magnesium Glycinate[cite: 1] | 5,000 mg (Bone preservation) | 500 mg | 3,500 mg (Skull-scavenging peak) | 2,000 mg (Maintenance)[cite: 1] |
| Waveguide Minerals[cite: 2] | Iron Oxide / Ferritin Compounds | 250 mg | 50 mg | 1,200 mg (Biogenic antenna lacing) | 400 mg |
| Vascular & Skeletal Matrix | Calcium Gluconate & Vitamin D3 | 8,500 mg (Counter-demineralization) | 400 mg | 4,000 mg (Skeletal growth delay offset) | 1,500 mg |
| Vascular & Skeletal Matrix | Bio-Flavonoids & Collagen Peptides | 12,000 mg (Vascular lining support) | 0 mg | 1,000 mg | 2,000 mg |
| Electrolyte System[cite: 1] | Sodium / Potassium Salts[cite: 1] | 1,500 mg | 800 mg | 2,200 mg | 4,500 mg (Ion-exchange replenishment)[cite: 1] |
| Carbohydrate Base | Dextrose / High-Dextrin Sugars | 40g | 20g | 80g | 160g (Rapid neural-bridge fuel)[cite: 1, 2] |
| Delivery Medium | Sterile Aqueous Suspension Base | QS (Quantity Sufficient) | QS (Quantity Sufficient) | QS (Quantity Sufficient) | QS (Quantity Sufficient) |
Formulation Breakdown Notes
1. Jenni Carisco — “Maternal Therapeutic Phase” (2225)
- Clinical Objective: Counteracting the rapid gestational demineralization mistakenly attributed solely to radiation exposure[cite: 1, 2].
- Pathology: The heavy emphasis on Calcium Gluconate (8,500 mg) and Vascular Bio-Flavonoids (12,000 mg) was designed to patch the “brittleness” in her blood vessels and stop her bones from dissolving[cite: 1]. The doctors did not yet realize that the fetuses were actively hijacking these minerals to construct their shared neural bridge, making the formula an uphill battle against evolutionary piracy[cite: 1, 2].
2. Celectra — “Neonatal Phase” (Infancy / Prematurity)
- Clinical Objective: Neuro-protection and basic thermal regulation[cite: 2].
- Pathology: Re-engineered by Dr. Cruiz immediately following the post-mortem discovery of where Jenni’s resources had gone[cite: 1, 2]. This batch slashed the heavy calcium load (to prevent premature skull fusion/ossification) and maxed out MCT Emulsions (450 mL)[cite: 1]. This provided direct ketones to keep the dual cortices synchronized while preserving her tiny 1.3 kg physical framework from cold shock[cite: 1, 2].
3. Celectra — “Mid-Childhood Phase” (Ages 5–12)
- Clinical Objective: Balancing standard skeletal elongation with the biogenic waveguide matrix[cite: 2].
- Pathology: Administered during her “failure to thrive” era[cite: 1, 2]. Her body was aggressively pulling raw materials to lace her skull bone-matrix with iron and magnesium[cite: 2]. Dr. Cruiz spiked the formulation with Iron Oxide (1,200 mg) and Magnesium Glycinate (3,500 mg)[cite: 1]. This targeted saturation deliberately ended the mineral scavenging behavior, allowing her physical height and weight to normalize, albeit well below average colony standards[cite: 2].
4. Celectra — “Young Adulthood Phase” (Age 16+)
- Clinical Objective: High-bandwidth communion stabilization and “Neural Brownout” prevention[cite: 1, 2].
- Pathology: The modern, mature iteration of the “Celectricity Shake”[cite: 1]. It features an extreme surge in Dextrose (160g) and Sodium/Potassium Salts (4,500 mg)[cite: 1]. At this stage, her skulls are fully mineralized; the formula is no longer building architecture, but maintaining the massive ion-exchange currents required to anchor her standing wave during planetary resonance events[cite: 1, 2].
Medical Contraindication
⚠️ Warning: If CMS-1 is withheld or diluted during periods of active or deep communion, glucose depletion occurs in under 15 minutes[cite: 2]. This triggers systemic autonomic desynchronization between the left and right bodies, resulting in immediate neurogenic shock, profound cardiovascular distress, and cognitive fragmentation[cite: 2].